Promoter-Driven DREADD Compositions for Retina-to-Locus Coeruleus Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic treatments for diseases and disorders of the nervous system lack cell-type specificity, leading to inefficacy and neurosurgical complications when targeting brain regions like the locus coeruleus.
Innovation Solution
Utilizing promoter-driven Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) expressed in retinal cells, specifically through the use of adeno-associated viral vectors, to stimulate targeted neurological pathways, particularly the locus coeruleus, via natural circuit inputs, avoiding direct brain injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If direct brain injection of DREADDs is used to target locus coeruleus, then cell-type specificity is improved, but neurosurgical risks and complexity increase
Solution Approach 1:
The patent uses the retina as an intermediary structure to deliver DREADDs indirectly to the locus coeruleus. By injecting DREADDs into the retina (a more accessible and safer location), the compounds naturally traffic through retinal ganglion cell axons to reach the locus coeruleus in the brain, avoiding direct brain surgery while achieving cell-type specificity.
Solution Approach 2:
The patent segments the delivery process into two distinct stages: first, delivery of DREADDs to the retina via safe intravitreal or subretinal injection; second, natural transport through retinal ganglion cell axons to the locus coeruleus. This segmentation allows the complex brain delivery task to be broken into safer, manageable steps.
2Reliability
If direct brain injection of DREADDs is used to target locus coeruleus, then treatment efficacy is improved, but procedural complexity increases
Solution Approach 1:
The patent employs the retinal ganglion cell axon pathway as a natural intermediary transport system. This biological highway automatically carries DREADDs from the retina to the locus coeruleus, eliminating the need for complex stereotactic brain injection procedures while maintaining reliable delivery to the target nucleus.
Solution Approach 2:
The patent leverages the body's own neural pathways to perform the delivery function. Retinal ganglion cells naturally project to the locus coeruleus, and this endogenous transport mechanism is harnessed to deliver DREADDs without requiring external surgical intervention in the brain, effectively making the biological system serve the delivery function.
3Adaptability or versatility
If non-specific therapeutic treatments are used for nervous system diseases, then treatment scope is improved, but cell-type specificity deteriorates
Solution Approach 1:
The patent applies local quality by making the DREADD expression location-specific through retinal targeting. The promoter-driven expression system ensures DREADDs are selectively expressed in retinal ganglion cells, and consequently in the locus coeruleus, providing localized modulation of this specific nucleus while leaving other brain regions unaffected.
Solution Approach 2:
The patent changes the spatial parameter of DREADD expression from diffuse brain injection to focused retinal delivery. This parameter change results in concentrated, specific expression in the locus coeruleus via natural axonal transport, transforming a non-specific treatment approach into a precisely targeted therapy.
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3F
AI summary
Methods and compositions for treating diseases or disorders of the nervous system using promoter-driven Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) and DREADD agonists are disclosed.